ActivX Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes

LA JOLLA, CA--(Marketwire - August 21, 2008) - Activx Biosciences, Inc., a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., announced today topline results from their Phase Ib and Phase IIa clinical trials with KRP-104, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for the treatment of type 2 diabetes. In Phase IIa, KRP-104 was shown to be well tolerated and efficacious in the treatment of hyperglycemia in patients with type 2 diabetes resulting in highly significant improvements in glycemic control compared to placebo.